NovaBridge Biosciences American Depositary Shares
Market Cap
200M
Short interest (Apr 30)
3.6%
Net Short (Jun 03 ): 0.0%
Borrow Fee
3.18%
↑ 5.9%
Available Shares
2M
↓ 40.6%
Price Chart
Company Overview
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.